Peripheral Neuropathy Market Set to Hit USD 2.66 Billion by 2035, Amid Rising Chronic Disease Burden – SNS Insider

Growing prevalence of diabetes and neurological disorders accelerates innovation in neuropathy treatment landscape.

Austin, United States, April 02, 2026 (GLOBE NEWSWIRE) — As per SNS Insider, The Peripheral Neuropathy Market was estimated at USD 1.56 billion in 2025 and is expected to reach USD 2.66 billion in 2035, growing at a CAGR of 5.46% during the forecast period of 2026-2035. The market is experiencing a steady growth due to an increased incidence of nerve disorders, along with increased awareness regarding early diagnosis and treatment. There have been significant developments in pharmacological and non-pharmacological treatment, leading to a shift in patient care with more effective treatment outcomes.

Get a Sample Report of Peripheral Neuropathy Market: https://www.snsinsider.com/sample-request/2707

The U.S. Peripheral Neuropathy Market has been valued at USD 0.56 Billion in 2025 and is expected to reach USD 0.93 Billion in 2035, growing at a CAGR of 5.21% from 2026 to 2035. Growth is driven by the rising prevalence of diabetes and chemotherapy-induced neuropathy, an aging population, increasing patient awareness, and adoption of advanced pharmacological and non-pharmacological therapies, supported by continuous research and innovation in treatment options.

Rising Prevalence of Diabetes and Chemotherapy-induced Neuropathy to Propel Growth Globally

The growing prevalence of chronic illnesses including diabetes, cancer, and HIV/AIDS is the main factor propelling the peripheral neuropathy market. Neuropathy is one of the main side effects of all these conditions. The market is also being driven by the development of new drug formulations and procedures, as well as a rise in patient awareness of the various pharmacological and non-pharmacological treatments. Additionally, the market has expanded due to advancements in neuropathy treatment.

Segmentation Analysis:

By Type

In 2025, Diabetic Peripheral Neuropathy dominated with 45% share due to the high global prevalence of diabetes and the associated risk of nerve damage. Chemotherapy-induced Peripheral Neuropathy is the fastest growing segment during 2026–2035 driven by the rising incidence of cancer and chemotherapy treatments. 

By Treatment

In 2025, Pharmacological Therapies dominated with 60% share due to the availability of pain relievers, anti-seizure medications, and antidepressants. Non-Pharmacological Therapies is the fastest growing segment during 2026–2035 due to the increased use of transcutaneous electrical nerve stimulations, plasma exchanges, and intravenous immune globulins.

By Distribution Channel

In 2025, Retail Pharmacies dominated with 50% share due to their widespread presence, trust factor among patients, and immediate availability of pharmacological therapy. Online Pharmacies is the fastest growing segment during 2026–2035 due to the growing acceptance of online shopping and the convenience of home delivery of medicines.

By End-User

In 2025, Hospitals and Clinics dominated with 55% share owing to advanced infrastructure, specialist care, and comprehensive neuropathy treatment programs. Ambulatory Centers is the fastest growing segment during 2026–2035 driven by convenience, outpatient care adoption, and cost-effective day-care solutions for neuropathy management.

Regional Insights:

The global peripheral neuropathy market is dominated by North America, which is projected to account for 40% of the market by 2025. The high prevalence of diabetes, cancer, and neurological conditions, particularly in the US, may be the cause of this market’s domination.

With a rapidly expanding diabetic patient population in nations, such as China and India, the Asia-Pacific peripheral neuropathy market has been shown to be the fastest-growing. Key growth factors for this market include things, such as better healthcare infrastructure, higher healthcare spending, and greater knowledge about neuropathy therapy. 

Need Any Customization Research on Peripheral Neuropathy Market, Enquire Now: https://www.snsinsider.com/enquiry/2707

Recent Developments:

• In 2025, Pfizer expanded its neuropathy portfolio with a next-generation topical analgesic for diabetic peripheral neuropathy, offering improved pain relief and faster patient response times.
• In 2024, Novartis introduced a novel sodium channel blocker for diabetic and chemotherapy-induced neuropathic pain, demonstrating enhanced efficacy and fewer side effects in clinical evaluations.

Major Peripheral Neuropathy Companies Analysis Listed in the Report:

• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• GlaxoSmithKline plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Amgen Inc.
• AbbVie Inc.
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Aurobindo Pharma Limited
• Lupin Limited
• Hikma Pharmaceuticals plc
• Viatris Inc.

Peripheral Neuropathy Market Segmentation

By Type

• Diabetic Peripheral Neuropathy
• Chemotherapy-induced Peripheral Neuropathy
• Idiopathic Peripheral Neuropathy
• HIV/AIDS Associated Peripheral Neuropathy

By Treatment

• Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Antidepressants
• Non-Pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Intravenous Immune Globulin
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User 

• Hospitals and Clinics
• Ambulatory Centers
• Others

Exclusive Sections of the Report (The USPs):

• DISEASE PREVALENCE & DIAGNOSIS METRICS – helps you understand global prevalence trends, rising incidence among diabetic and elderly populations, and growth in diagnosed neuropathy cases due to improved screening.
• TREATMENT & THERAPY ADOPTION METRICS – helps you evaluate the use of pharmacological and non-pharmacological treatments, combination therapy adoption, and uptake of advanced therapies such as neurostimulation.
• HEALTHCARE UTILIZATION & COST METRICS – helps you analyze treatment costs, care delivery settings, and out-of-pocket expenditure trends for long-term neuropathy management.
• PHARMACEUTICAL R&D & CLINICAL DEVELOPMENT METRICS – helps you track clinical trial activity, investment in innovative therapies, and pipeline advancements in neuropathic pain treatment.
• DIGITAL HEALTH & MONITORING TECHNOLOGY METRICS – helps you assess adoption of wearable devices and digital health solutions for continuous monitoring and pain management.
• PATIENT CARE & TREATMENT ACCESS METRICS – helps you understand patient access to therapies across hospitals, clinics, and ambulatory care settings, along with evolving treatment pathways.

Purchase Single User PDF of Peripheral Neuropathy Market Report (20% Discount): https://www.snsinsider.com/checkout/2707

Peripheral Neuropathy Market Report Scope

Related Reports

Neurostimulation Devices Market

Pain Management Market

Diabetic Neuropathy Market

Neuropathic Pain Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: [email protected] 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. DailyIndiaNews.com takes no editorial responsibility for the same.